Obstructive Sleep Apnea-induced Cor Pulmonale

Obstructive Sleep Apnea-Induced Cor Pulmonale: A Comprehensive Medical Guide

Introduction and Definition

Obstructive Sleep Apnea-induced Cor Pulmonale (OSA-CP), also known as secondary pulmonary hypertension due to obstructive sleep apnea, is a serious cardiovascular complication arising from untreated or inadequately treated obstructive sleep apnea (OSA). It represents a significant progression of OSA, where the repeated episodes of upper airway collapse during sleep lead to chronic intermittent hypoxia and hypercapnia. These physiological insults, in turn, trigger adaptive and maladaptive changes within the pulmonary vasculature and the right ventricle of the heart, ultimately resulting in right ventricular hypertrophy and dysfunction.

This condition is classified under ICD-10 code I27.81, specifically within the category of other pulmonary heart diseases. As a specialist in cardiovascular medicine, it is crucial to understand the intricate mechanisms linking sleep-disordered breathing to cardiac pathology, as early recognition and aggressive management can significantly alter the patient's prognosis.

Detailed Pathophysiology, Etiology, and Risk Factors

The development of OSA-induced Cor Pulmonale is a complex, multi-step process driven by the recurrent respiratory events characteristic of OSA.

Pathophysiology

1. Intermittent Hypoxia and Hypercapnia: During apneic or hypopneic events in OSA, airflow is significantly reduced or completely obstructed, leading to a drop in arterial oxygen saturation (SpO2) and a rise in arterial carbon dioxide levels (PaCO2). These fluctuations are not merely transient; they occur repeatedly throughout the sleep period, creating a state of chronic intermittent hypoxia and systemic inflammation.

2. Pulmonary Vasoconstriction: The hypoxic environment directly stimulates the pulmonary arteries to constrict. This is mediated by several factors, including:

   • Endothelial Dysfunction: Hypoxia impairs the function of the pulmonary artery endothelium, reducing the production of vasodilators like nitric oxide (NO) and prostacyclin (PGI2), while increasing the production of vasoconstrictors like endothelin-1.
   • Increased Sympathetic Tone: OSA leads to heightened sympathetic nervous system activity, which further contributes to pulmonary vasoconstriction.
   • Chemoreceptor Activation: Peripheral and central chemoreceptors are stimulated by hypoxia and hypercapnia, relaying signals that promote pulmonary vasoconstriction.

3. Pulmonary Vascular Remodeling: Chronic and recurrent vasoconstriction, coupled with inflammatory mediators released during hypoxic episodes, promotes structural changes in the pulmonary arteries. This includes:

   • Intimal Hyperplasia: Thickening of the inner lining of the arteries.
   • Media Hypertrophy: Thickening of the muscular layer of the arteries.
   • Adventitial Thickening: Thickening of the outer layer.
   • Neovascularization: Formation of new, abnormal blood vessels within the arterial walls.
     These structural changes lead to increased pulmonary vascular resistance (PVR), a hallmark of pulmonary hypertension.

4. Right Ventricular Adaptation and Failure: As PVR increases, the right ventricle (RV) must generate higher pressures to pump blood through the pulmonary circulation. Initially, the RV adapts through hypertrophy (thickening of its muscle wall), which maintains cardiac output. However, with sustained pressure overload, the RV eventually decompresses, leading to dilation and systolic dysfunction. This RV failure results in increased RV end-diastolic pressure, which impedes venous return to the heart, causing systemic venous congestion and reduced forward cardiac output.

5. Other Contributing Factors:

   • Pulmonary Artery Endothelial Dysfunction: Beyond hypoxia, inflammation and oxidative stress contribute to impaired endothelial function.
   • Increased Pulmonary Blood Volume: During apneic events, there can be a shift of blood volume into the thoracic circulation, further stressing the pulmonary vasculature.
   • Left Ventricular Dysfunction: While the primary insult is to the right heart, severe OSA can also impact left ventricular function through shared mechanisms of hypoxia, inflammation, and sympathetic overactivity.

Etiology

The primary etiology of OSA-induced Cor Pulmonale is Obstructive Sleep Apnea (OSA). OSA is characterized by recurrent episodes of complete (apnea) or partial (hypopnea) collapse of the upper airway during sleep, despite continued respiratory effort.

Risk Factors for OSA-Induced Cor Pulmonale

While OSA is the underlying cause, certain factors increase the likelihood of developing Cor Pulmonale in individuals with OSA:

• Severity of OSA: Higher Apnea-Hypopnea Index (AHI) and more profound oxygen desaturation events are strongly associated with increased risk.
• Duration of OSA: Longer duration of untreated OSA.
• Obesity: Central obesity is a major risk factor for OSA. Excess adipose tissue, particularly around the neck, narrows the airway. Obesity also contributes to systemic inflammation and endothelial dysfunction.
• Male Sex: Men are more commonly diagnosed with OSA and tend to have a higher risk of cardiovascular complications, including Cor Pulmonale.
• Age: Older individuals may have reduced respiratory drive and less elastic airways, predisposing them to more severe OSA and its complications.
• Coexisting Pulmonary Diseases: Conditions like Chronic Obstructive Pulmonary Disease (COPD), asthma, or interstitial lung disease can exacerbate hypoxia and pulmonary hypertension, increasing the risk.
• Cardiovascular Risk Factors: Hypertension, diabetes mellitus, dyslipidemia, and smoking can further impair vascular health and contribute to the progression of pulmonary hypertension and right heart failure.
• Genetics: A familial predisposition to sleep-disordered breathing or pulmonary vascular reactivity may play a role.

Signs, Symptoms, and Clinical Presentation

The clinical presentation of OSA-induced Cor Pulmonale is often a combination of symptoms related to OSA itself, pulmonary hypertension, and right heart failure. Many patients may have a long history of undiagnosed or poorly managed OSA.

Symptoms of Obstructive Sleep Apnea:

• Excessive Daytime Sleepiness (EDS): The most common symptom, characterized by an overwhelming urge to sleep during waking hours, even after a full night's sleep.
• Loud Snoring: Often described as disruptive and intermittent, with periods of silence (apneas).
• Witnessed Apneas: Episodes where a bed partner observes the patient stopping breathing during sleep.
• Morning Headaches: Due to nocturnal hypercapnia and hypoxia.
• Difficulty Concentrating and Memory Problems: Cognitive impairment secondary to sleep fragmentation and hypoxia.
• Irritability and Mood Swings: Emotional lability.
• Nocturia: Frequent urination at night.

Symptoms of Pulmonary Hypertension and Right Heart Failure (Cor Pulmonale):

As the condition progresses, symptoms attributable to pulmonary hypertension and subsequent right ventricular dysfunction become more prominent:

• Dyspnea (Shortness of Breath): Initially on exertion, progressing to dyspnea at rest. This is a cardinal symptom.
• Fatigue and Weakness: Due to reduced cardiac output and systemic hypoperfusion.
• Edema: Swelling in the lower extremities (ankles, legs) due to fluid retention secondary to increased venous pressure.
• Abdominal Distension (Ascites): Fluid accumulation in the abdominal cavity, indicative of severe right heart failure.
• Hepatomegaly: Enlargement of the liver due to venous congestion.
• Jugular Venous Distension (JVD): Prominent veins in the neck, reflecting elevated central venous pressure.
• Cyanosis: A bluish discoloration of the skin and mucous membranes, particularly in the lips and nail beds, due to severe hypoxemia.
• Chest Pain (Angina): Can occur due to RV ischemia or increased myocardial oxygen demand.
• Palpitations: Awareness of an irregular or rapid heartbeat.
• Weight Gain: Due to fluid retention.

It is important to note that many patients may attribute their symptoms (especially fatigue and dyspnea) to aging, deconditioning, or other comorbidities, leading to delayed diagnosis.

Standard Diagnostic Evaluation & Workup

A thorough diagnostic workup is essential to confirm the diagnosis of OSA-induced Cor Pulmonale, differentiate it from other causes of pulmonary hypertension and right heart failure, and assess its severity.

1. History and Physical Examination

• Detailed sleep history (snoring, witnessed apneas, daytime sleepiness).
• Assessment for cardiovascular risk factors and symptoms of right heart failure.
• Physical exam findings may include elevated jugular venous pressure, peripheral edema, hepatomegaly, and a loud P2 heart sound.

2. Polysomnography (PSG) - The Gold Standard for OSA Diagnosis

• Definition: Polysomnography is the gold standard for diagnosing sleep apnea. It is an overnight sleep study that monitors various physiological parameters.
• Parameters Monitored:
  • Electroencephalogram (EEG): Brain waves to determine sleep stages.
  • Electrooculogram (EOG): Eye movements.
  • Electromyogram (EMG): Muscle activity (chin and leg).
  • Electrocardiogram (ECG): Heart rhythm.
  • Respiratory Effort Bands: Thoracic and abdominal movement to assess breathing effort.
  • Airflow Sensors: Nasal cannula and/or thermistor to measure airflow.
  • Oxygen Saturation (SpO2): Pulse oximetry.
  • End-tidal CO2 (EtCO2): Measures carbon dioxide levels at the end of exhalation.
  • Audio Recording: To capture snoring.
• Key Metric: The Apnea-Hypopnea Index (AHI) is calculated, representing the average number of apneas and hypopneas per hour of sleep. An AHI of 15 or more, or an AHI of 5 or more with symptoms of OSA, confirms the diagnosis.
• Significance for OSA-CP: The severity of AHI, nadir SpO2, and the frequency of desaturation events during PSG are crucial in assessing the risk and severity of OSA-induced pulmonary hypertension.

3. Imaging Studies

• Chest X-ray (CXR):

  • May show signs of cardiomegaly (enlarged heart), particularly right ventricular enlargement.
  • Can reveal signs of pulmonary venous congestion or pleural effusions.
  • May show hyperinflation of the lungs in some cases.
  • Often normal in early stages.

• Echocardiography (Transthoracic Echocardiogram - TTE):

  • Primary Role: Non-invasive assessment of right ventricular size and function, and estimation of pulmonary artery systolic pressure (PASP).
  • Findings:
    • Right ventricular dilation and hypertrophy.
    • Paradoxical septal motion (flattening or bowing of the interventricular septum).
    • Tricuspid regurgitation (TR) jet velocity, used to estimate RV systolic pressure. Elevated TR velocity > 3.4 m/s, particularly in the context of OSA symptoms, suggests pulmonary hypertension.
    • Assessment of left ventricular function.
    • Evaluation of other cardiac structures.

• Computed Tomography Pulmonary Angiography (CTPA):

  • Primarily used to rule out pulmonary embolism (PE) as a cause of pulmonary hypertension.
  • Can also reveal signs of pulmonary vascular remodeling (e.g., thickening of pulmonary artery walls) and chronic thromboembolic pulmonary hypertension (CTEPH).

• Ventilation-Perfusion (V/Q) Scan:

  • An alternative to CTPA for ruling out PE, especially in patients with contrast allergies or renal insufficiency.

4. Cardiac Catheterization (Right Heart Catheterization - RHC) - The Gold Standard for Pulmonary Hypertension Diagnosis

• Definition: An invasive procedure where a catheter is inserted into a vein and advanced into the right side of the heart and pulmonary artery.
• Primary Role: Definitive diagnosis and quantification of pulmonary hypertension and assessment of hemodynamics.
• Parameters Measured:
  • Right Atrial Pressure (RAP)
  • Right Ventricular Pressure (RVP)
  • Pulmonary Artery Pressure (PAP)
  • Pulmonary Artery Wedge Pressure (PAWP)
  • Cardiac Output (CO)
  • Pulmonary Vascular Resistance (PVR)
• Diagnostic Criteria for Pulmonary Hypertension: Mean Pulmonary Artery Pressure (mPAP) ≥ 20 mmHg at rest.
• Significance for OSA-CP: RHC is crucial for confirming pulmonary hypertension, determining its severity (e.g., pre-capillary vs. post-capillary), and assessing the response to treatment. It helps differentiate OSA-induced pulmonary hypertension from other etiologies.

5. Laboratory Tests

• Arterial Blood Gas (ABG):
  • Can reveal hypoxemia (low PaO2) and/or hypercapnia (high PaCO2), particularly if drawn during sleep or in a patient with significant hypoventilation.
• Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP):
  • Elevated levels indicate myocardial stretch and are indicative of heart failure, particularly right ventricular strain.
• Complete Blood Count (CBC):
  • May reveal polycythemia (elevated red blood cell count) in response to chronic hypoxia.
• Liver Function Tests (LFTs):
  • Elevated transaminases and bilirubin can indicate hepatic congestion due to right heart failure.
• Renal Function Tests:
  • To assess kidney function, which can be affected by reduced cardiac output and fluid retention.
• Thyroid Function Tests:
  • To rule out thyroid dysfunction as a contributor to cardiac symptoms.

6. Pulmonary Function Tests (PFTs)

• While OSA-CP is primarily a pulmonary vascular and right heart issue, PFTs can help assess for underlying or coexisting lung diseases (e.g., COPD, restrictive lung disease) that might contribute to pulmonary hypertension. They typically show normal lung volumes and diffusion capacity unless another lung disease is present.

7. Right Ventricular Biopsy (Rarely Performed)

• In select cases, particularly when the diagnosis is uncertain or to assess specific vascular pathologies, a right ventricular or pulmonary artery biopsy might be considered, but this is not standard practice for OSA-CP.

Therapeutic Interventions

The management of OSA-induced Cor Pulmonale requires a multi-faceted approach, focusing on treating the underlying OSA, managing pulmonary hypertension, and addressing right heart failure.

1. Treatment of Obstructive Sleep Apnea (OSA)

This is the cornerstone of therapy for OSA-induced Cor Pulmonale. Effective treatment of OSA can significantly improve pulmonary hemodynamics and reverse right ventricular dysfunction.

• Continuous Positive Airway Pressure (CPAP):

  • Mechanism: CPAP delivers pressurized air through a mask worn during sleep, keeping the upper airway open and preventing apneas and hypopneas.
  • Efficacy: This is the most effective treatment for moderate to severe OSA and has been shown to reduce pulmonary artery pressures, improve RV function, and alleviate symptoms of Cor Pulmonale.
  • Adherence: Ensuring good patient adherence and mask comfort is crucial for success.

• Other Positive Airway Pressure Devices:

  • Automatic Positive Airway Pressure (APAP): Adjusts pressure automatically based on breathing patterns.
  • Bilevel Positive Airway Pressure (BiPAP): Provides different pressures for inspiration and expiration, which may be better tolerated by some patients.

• Oral Appliances:

  • Mandibular advancement devices (MADs) can be effective for mild to moderate OSA but are generally less effective for severe OSA or when significant Cor Pulmonale is present.

• Surgical Interventions for OSA (Less Common for Cor Pulmonale):

  • Uvulopalatopharyngoplasty (UPPP), genioglossus advancement, maxillomandibular advancement, and hypoglossal nerve stimulation are options for select patients with OSA but are typically considered when CPAP is not tolerated or effective, and their impact on established Cor Pulmonale is less pronounced than CPAP.

2. Pharmacotherapy for Pulmonary Hypertension and Right Heart Failure

While treating OSA is paramount, pharmacologic agents are often used to manage the symptoms and hemodynamic consequences of pulmonary hypertension and right heart failure.

• Diuretics:

  • Purpose: To reduce fluid overload and edema associated with right heart failure.
  • Examples: Furosemide, bumetanide, spironolactone.
  • Caution: Excessive diuresis can lead to dehydration and worsen RV afterload if not carefully monitored.

• Vasodilators (Used with caution and often guided by RHC):

  • Purpose: To reduce pulmonary vascular resistance.
  • Examples: Calcium channel blockers (e.g., nifedipine, diltiazem) are sometimes used in specific subtypes of pulmonary hypertension but are less effective in OSA-induced PH unless a vasoreactive component is identified.
  • Specific Pulmonary Arterial Hypertension (PAH) Therapies: While not standard for OSA-CP due to the underlying treatable cause (OSA), in severe, refractory cases where OSA is optimized and PH persists, agents like prostacyclin analogs, endothelin receptor antagonists, or PDE-5 inhibitors might be considered off-label or in specialized centers, but their efficacy and safety in this specific context require careful consideration.

• Oxygen Therapy:

  • Purpose: To correct hypoxemia, reduce pulmonary vasoconstriction, and improve RV function.
  • Indication: Supplemental oxygen is often prescribed, especially during sleep and for patients with persistent hypoxemia. Titration should be guided by SpO2 monitoring.

• Anticoagulation:

  • Role: Controversial for OSA-CP. May be considered in patients with coexisting conditions like pulmonary embolism or severe RV dysfunction, but not routinely recommended for OSA-CP alone.

• Management of Comorbidities:

  • Aggressive management of hypertension, diabetes, dyslipidemia, and obesity is crucial.

3. Lifestyle Modifications

• Weight Loss: For obese patients, significant weight loss can reduce the severity of OSA and improve cardiovascular health.
• Salt Restriction: To help manage fluid retention and edema.
• Regular Exercise: As tolerated, to improve overall cardiovascular fitness and functional capacity.
• Smoking Cessation: Essential for improving pulmonary and cardiovascular health.
• Alcohol Avoidance: Alcohol can worsen OSA and suppress respiratory drive.

4. Cardiac Rehabilitation

• A supervised exercise program can help patients improve their functional capacity, manage symptoms, and enhance their quality of life.

Long-Term Prognosis

The long-term prognosis for OSA-induced Cor Pulmonale is variable and depends heavily on several factors:

• Timeliness and Effectiveness of OSA Treatment: This is the single most important determinant of prognosis. Aggressive and consistent treatment of OSA with CPAP can lead to significant improvement in RV function and pulmonary pressures, potentially reversing some of the damage and preventing further progression.
• Severity of Pulmonary Hypertension and RV Dysfunction at Diagnosis: Patients presenting with severe pulmonary hypertension and established right heart failure have a poorer prognosis.
• Presence of Comorbidities: Coexisting lung diseases, cardiovascular disease, and other chronic conditions can negatively impact outcomes.
• Patient Adherence to Treatment: Consistent use of CPAP, adherence to medications, and lifestyle modifications are critical.
• Early Diagnosis: Earlier diagnosis and intervention generally lead to better outcomes.

Key Prognostic Indicators:

• Persistence of Pulmonary Hypertension despite OSA Treatment: If pulmonary pressures remain elevated after optimal OSA management, the prognosis is poorer.
• Right Ventricular Ejection Fraction (RVEF): A reduced RVEF is associated with a worse prognosis.
• Functional Class (NYHA/WHO): Patients in higher functional classes (e.g., NYHA Class III or IV) have a worse prognosis.
• Hemodynamic Parameters: High PVR and low cardiac output on RHC are associated with worse outcomes.
• Hospitalization Rates: Frequent hospitalizations for heart failure exacerbations indicate a poor prognosis.

Potential Outcomes:

• Reversal/Improvement: With effective OSA treatment, many patients can experience significant improvement in symptoms, RV function, and pulmonary hemodynamics. This can lead to a reduced risk of further complications and improved quality of life.
• Stabilization: In some cases, treatment may stabilize the condition, preventing further deterioration.
• Progression: If OSA is not adequately treated or if the disease is very advanced at diagnosis, the condition can progress, leading to worsening right heart failure, arrhythmias, and increased risk of sudden cardiac death.
• Need for Advanced Therapies: In rare, refractory cases, patients may eventually require evaluation for advanced therapies such as lung transplantation or even heart-lung transplantation, though this is uncommon for OSA-induced PH.

In summary, OSA-induced Cor Pulmonale is a serious but often treatable complication of obstructive sleep apnea. A comprehensive approach focusing on accurate diagnosis through polysomnography and cardiac evaluation, followed by aggressive treatment of OSA with CPAP, and appropriate medical management of pulmonary hypertension and right heart failure, offers the best chance for improving patient outcomes and long-term survival.

Frequently Asked Questions (FAQ)

1. What is Cor Pulmonale caused by Sleep Apnea?
Cor Pulmonale caused by sleep apnea, also known as Obstructive Sleep Apnea-induced Cor Pulmonale (OSA-CP), is a condition where untreated or poorly managed obstructive sleep apnea leads to high blood pressure in the arteries of the lungs (pulmonary hypertension). This increased pressure forces the right side of the heart to work harder, eventually causing it to enlarge and weaken, leading to heart failure.

2. How does Sleep Apnea cause Heart Problems like Cor Pulmonale?
During sleep apnea, repeated episodes of blocked breathing cause drops in blood oxygen levels (hypoxia) and surges in carbon dioxide. This triggers the blood vessels in the lungs to constrict. Over time, this repeated constriction and the body's inflammatory response cause the lung arteries to thicken and narrow (pulmonary vascular remodeling), increasing resistance to blood flow. The right ventricle of the heart must then pump against this higher resistance, leading to its enlargement and eventual failure.

3. What are the early signs and symptoms of OSA-induced Cor Pulmonale?
Early symptoms can be subtle and may be mistaken for other conditions. They often include worsening shortness of breath (dyspnea), especially with exertion, fatigue, and swelling in the legs and ankles (edema). Patients may also experience symptoms of their underlying sleep apnea, such as loud snoring, daytime sleepiness, and morning headaches.

4. What is the "gold standard" test to diagnose Obstructive Sleep Apnea?
The gold standard test for diagnosing obstructive sleep apnea is Polysomnography (PSG), commonly known as an overnight sleep study. This test monitors various physiological functions during sleep, including brain waves, eye movements, muscle activity, heart rhythm, breathing effort, airflow, and blood oxygen levels.

5. How is Pulmonary Hypertension in Sleep Apnea diagnosed and confirmed?
Pulmonary hypertension is typically suspected based on symptoms and confirmed with imaging like echocardiography, which can estimate pulmonary artery pressures. The definitive diagnosis and assessment of its severity are made through right heart catheterization (RHC), an invasive procedure that directly measures pressures in the heart and pulmonary arteries.

6. What is the primary treatment for OSA-induced Cor Pulmonale?
The most crucial and primary treatment is effective management of the underlying Obstructive Sleep Apnea (OSA). This is most commonly achieved with Continuous Positive Airway Pressure (CPAP) therapy. By keeping the airway open during sleep, CPAP reduces hypoxic episodes, lowers pulmonary artery pressure, and can help reverse right ventricular strain.

7. Besides CPAP, what other treatments are used for OSA-induced Cor Pulmonale?
Other treatments focus on managing the consequences of pulmonary hypertension and right heart failure. These include:
* Diuretics: To reduce fluid retention and swelling.
* Supplemental Oxygen: To improve blood oxygen levels.
* Medications for Pulmonary Hypertension: In some severe cases, specific drugs used for pulmonary arterial hypertension may be considered.
* Lifestyle Modifications: Weight loss, salt restriction, exercise, and smoking cessation are also important.

8. Can Cor Pulmonale from Sleep Apnea be reversed?
Yes, to a significant extent. If diagnosed and treated early, the pulmonary hypertension and right ventricular dysfunction associated with OSA-induced Cor Pulmonale can often be improved or even reversed with consistent and effective treatment of OSA, primarily CPAP therapy. However, if the condition is advanced or left untreated for a long time, some damage may be permanent.

9. What is the long-term outlook for someone with OSA-induced Cor Pulmonale?
The long-term prognosis is variable and depends heavily on the effectiveness of OSA treatment, the severity of the condition at diagnosis, and the presence of other health issues. With prompt and consistent CPAP therapy, many patients can achieve significant improvement and a good quality of life. Without adequate treatment, the condition can progress, leading to severe heart failure and increased mortality.

10. Is OSA-induced Cor Pulmonale the same as other types of Pulmonary Hypertension?
No, while it results in pulmonary hypertension, OSA-induced Cor Pulmonale is a specific type categorized as Group 3 Pulmonary Hypertension (Pulmonary Hypertension due to Lung Diseases and/or Hypoxia) by the World Health Organization (WHO). Its key distinction is that the primary driver is a treatable sleep-disordered breathing condition, offering a unique therapeutic pathway compared to other forms of pulmonary hypertension.

Related Clinical Integration

In the management of Obstructive Sleep Apnea-induced Cor Pulmonale, a multidisciplinary approach is essential to address both the underlying nocturnal respiratory failure and the resulting right-sided heart strain. The diagnostic foundation relies on Polysomnography (Diagnostic Sleep Study) / تخطيط النوم المتعدد (دراسة تشخيصية للنوم) (فحص بالمنظار أو أخذ عينات) to quantify apnea severity, which directly informs the prescription of a CPAP Machine / جهاز ضغط مجرى الهواء الإيجابي المستمر (CPAP) (أجهزة التنفس الصناعي ودعم الأكسجين) as the primary intervention to alleviate pulmonary hypertension. For patients presenting with persistent hypoxemia, supplemental support via an Oxygen Concentrator / مكثف الأكسجين (معدات طبية عامة) may be required, while Diuretics / مدرات البول Standard are utilized to manage systemic fluid overload secondary to right ventricular dysfunction. In complex cases where tissue oxygenation remains compromised, Hyperbaric oxygen therapy / العلاج بالأكسجين عالي الضغط (خدمات رعاية عامة) may be considered as an adjunctive measure to improve cellular perfusion and mitigate the systemic sequelae of chronic hypoxia.